December 16, 2020
CASI Pharmaceuticals Announces Appointment Of Chief Financial OfficerNovember 18, 2020
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)November 09, 2020
CASI Pharmaceuticals Announces Third Quarter 2020 Financial ResultsNovember 05, 2020
CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020October 27, 2020
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China regionOctober 02, 2020
CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual MeetingSeptember 29, 2020
CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy LtdSeptember 11, 2020
CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September ConferencesAugust 10, 2020
CASI Pharmaceuticals Announces Second Quarter 2020 Financial ResultsAugust 03, 2020
CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020July 22, 2020
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common StockJuly 21, 2020
CASI Pharmaceuticals Announces Proposed Public Offering Of Common StockJune 08, 2020
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody ProgramJune 02, 2020
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare ConferenceMay 11, 2020
CASI Pharmaceuticals Announces First Quarter 2020 Financial ResultsApril 07, 2020
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor ConferenceMarch 16, 2020
CASI Pharmaceuticals Announces Full Year 2019 Financial ResultsDecember 03, 2019
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial ApplicationsNovember 12, 2019
CASI Pharmaceuticals Announces Third Quarter 2019 Financial ResultsNovember 07, 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
